Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables (2017 - 2025)

Historic Receivables for Aclaris Therapeutics (ACRS) over the last 9 years, with Q2 2025 value amounting to $194000.0.

  • Aclaris Therapeutics' Receivables fell 7228.57% to $194000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $194000.0, marking a year-over-year decrease of 7228.57%. This contributed to the annual value of $318000.0 for FY2024, which is 671.14% up from last year.
  • As of Q2 2025, Aclaris Therapeutics' Receivables stood at $194000.0, which was down 7228.57% from $250000.0 recorded in Q1 2025.
  • In the past 5 years, Aclaris Therapeutics' Receivables registered a high of $963000.0 during Q2 2021, and its lowest value of $194000.0 during Q2 2025.
  • In the last 5 years, Aclaris Therapeutics' Receivables had a median value of $540500.0 in 2022 and averaged $531777.8.
  • As far as peak fluctuations go, Aclaris Therapeutics' Receivables surged by 6241.3% in 2024, and later crashed by 7228.57% in 2025.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Receivables stood at $647000.0 in 2021, then fell by 25.19% to $484000.0 in 2022, then plummeted by 38.43% to $298000.0 in 2023, then increased by 6.71% to $318000.0 in 2024, then tumbled by 38.99% to $194000.0 in 2025.
  • Its Receivables stands at $194000.0 for Q2 2025, versus $250000.0 for Q1 2025 and $318000.0 for Q4 2024.